Murchinson Ltd. Takes $152,000 Position in Werewolf Therapeutics, Inc. (NASDAQ:HOWL)

Murchinson Ltd. bought a new position in Werewolf Therapeutics, Inc. (NASDAQ:HOWL) during the 2nd quarter, HoldingsChannel reports. The fund bought 62,500 shares of the company’s stock, valued at approximately $152,000.

Other hedge funds also recently made changes to their positions in the company. American Century Companies Inc. grew its holdings in Werewolf Therapeutics by 50.7% in the 2nd quarter. American Century Companies Inc. now owns 37,634 shares of the company’s stock worth $92,000 after acquiring an additional 12,656 shares during the last quarter. Point72 DIFC Ltd bought a new stake in shares of Werewolf Therapeutics in the second quarter worth about $34,000. Lighthouse Investment Partners LLC purchased a new position in Werewolf Therapeutics during the 4th quarter valued at about $87,000. Denali Advisors LLC bought a new position in Werewolf Therapeutics during the 1st quarter valued at approximately $172,000. Finally, Rhumbline Advisers purchased a new stake in Werewolf Therapeutics in the 2nd quarter worth approximately $79,000. 64.84% of the stock is owned by hedge funds and other institutional investors.

Werewolf Therapeutics Stock Up 1.0 %

HOWL stock opened at $2.12 on Friday. Werewolf Therapeutics, Inc. has a fifty-two week low of $1.57 and a fifty-two week high of $8.19. The company has a market capitalization of $92.12 million, a price-to-earnings ratio of -1.94 and a beta of 0.46. The business’s 50 day moving average price is $2.21 and its two-hundred day moving average price is $3.76. The company has a debt-to-equity ratio of 0.24, a quick ratio of 12.13 and a current ratio of 12.13.

Werewolf Therapeutics (NASDAQ:HOWL) last issued its quarterly earnings results on Thursday, August 8th. The company reported ($0.43) earnings per share for the quarter, missing the consensus estimate of ($0.38) by ($0.05). The firm had revenue of $1.14 million during the quarter, compared to analysts’ expectations of $2.00 million. Werewolf Therapeutics had a negative return on equity of 48.25% and a negative net margin of 578.80%. As a group, analysts forecast that Werewolf Therapeutics, Inc. will post -1.64 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

HOWL has been the topic of several research analyst reports. JMP Securities reissued a “market outperform” rating and set a $12.00 target price on shares of Werewolf Therapeutics in a research note on Wednesday, June 26th. Wedbush reissued an “outperform” rating and set a $9.00 price objective on shares of Werewolf Therapeutics in a research report on Monday, June 3rd. Finally, HC Wainwright restated a “buy” rating and issued a $15.00 price objective on shares of Werewolf Therapeutics in a report on Tuesday, July 2nd.

About Werewolf Therapeutics

Werewolf Therapeutics, Inc, a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies.